Zanubrutinib for the treatment of patients with del(17p) and/or <i>TP53</i> CLL/SLL: analysis across clinical studies
Constantine S. Tam(The Alfred Hospital), Jennifer R. Brown(Dana-Farber Cancer Institute), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Kamel Laribi(Centre Hospitalier du Mans), Talha Munir(Leeds Teaching Hospitals NHS Trust), Tommi Salmi(Düsseldorf University Hospital), Remus Vezan(National University of Misiones), Megan Wang(National University of Misiones), Kenneth K. Wu(Illinois College), Andy H. Szeto(National University of Misiones), Mazyar Shadman(University of Washington), Heather Allewelt(National University of Misiones), Anders Österborg(Karolinska University Hospital), Martin Šimkovič(Charles University), Paolo Ghia(Vita-Salute San Raffaele University), Stephen Opat(Monash Health), Mary Ann Anderson(The Royal Melbourne Hospital), Jessica Li(Universidad San Carlos), Ian W. Flinn(Tennessee Oncology), Linlin Xu(Nanchang University), Gavin Cull(Sir Charles Gairdner Hospital)
Cited by 2
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k